Soleno Therapeutics Inc
$71.42
(as of Mar 31, 3:59 PM EST)
Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.
Ticker Information for Soleno Therapeutics Inc
Stock Price
$71.42
Ticker Symbol
SLNO
Exchange
NASDAQ
Industry Information for Soleno Therapeutics Inc
Sector
Healthcare
Industry
Biotechnology
Company Description for Soleno Therapeutics Inc
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
Fundamentals for Soleno Therapeutics Inc
Market Capitalization
$3,301,266,944
EBITDA
$-182,442,000
Dividends per Share
P/E Ratio
Forward P/E Ratio
0
Earnings per Share
$-4.38
Earnings per Share Estimate Next Year
Profit Margin
Shares Outstanding
45,857,300
Percent Owned by Insiders
2.93%
Percent Owned by Institutions
113.72%
52-Week High
52-Week Low
Technical Indicators for Soleno Therapeutics Inc
Analyst Ratings for Soleno Therapeutics Inc
Strong Buy
4
Buy
3
Hold
0
Sell
0
Strong Sell
0
News About Soleno Therapeutics Inc
Mar 29, 2025, 10:39 PM EST
We recently published a list of 10 Stocks Outperform Broader Market Last Week. See more.
Mar 28, 2025, 10:30 PM EST
We recently published a list of 10 Firms End Friday Strong; 3 Reach All-Time Highs. See more.
Mar 28, 2025, 4:25 AM EST
We recently published a list of 10 Stocks Jump, Defy Market Uncertainties on Thursday. See more.
Mar 26, 2025, 5:15 PM EST
First approved therapy to address hyperphagia in individuals with Prader-Willi syndrome
See more.